Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response

Table 1 Drug preparations and treatment details

Drug	Supplier	Preparation^a	PDX assay^b	MiniPDX assay^b
S-1	Hengrui	0.5% HPMC + 0.2% Tween 80	10 mg/kg, po, qd*5/w	10 mg/kg, po, qd*5
Docetaxel	DEMO	5% Tween 80 + 5% Ethanol + 90% Saline	20 mg/kg, ip, q4d	20 mg/kg, ip, q4d*2
Gemzar	Eli Lilly	Saline	60 mg/kg, ip, q4d	60 mg/kg, ip, q4d*2
Oxaliplatin	Hengrui	5% Glucose	5 mg/kg, ip, biw	5 mg/kg, ip, q4d*2
Irinotecan	DEMO	5% DMSO + 95% Saline	40 mg/kg, ip, q4d	50 mg/kg, ip, q4d*2
Cisplatin	Hansoh	Saline	5 mg/kg, ip, qw	5 mg/kg, ip, q4d*2
Epirubicin	Pfizer	Saline	5 mg/kg, ip, qw	5 mg/kg, ip, q4d*2
Capecitabine	Adamas	0.5% HPMC + 0.2% Tween 80	400 mg/kg, po, qd*14	400 mg/kg, po, qd*7
5-FU	Xudong-Haipu	Saline	25 mg/kg, ip, qd*5/w	25 mg/kg, ip, qd*5
Erlotinib	Topscience	0.5% HPMC + 0.2% Tween 80	50 mg/kg, po, qd	50 mg/kg, po, qd*7
Crizotinib	Aladdin	0.5% HPMC + 0.2% Tween 80	50 mg/kg, po, qd	50 mg/kg, po, qd*7
AZD9291	Topscience	0.5% HPMC + 0.2% Tween 80	5 mg/kg, po, qd	5 mg/kg, po, qd*7

po oral, ip intraperitoneal, qd once a day, biw twice a week, qw once a week, q4d once every 4 days
^a Recipe of formulation
^b Dose, dosing route, dosing frequency followed by, where indicated, dosing times and/or treatment duration

ISSN: 2523-3548